Biodefense Market Size 2030 - Global Industry Sales, Revenue, Consumption Value and more

Fairfield Market Research, a leading market intelligence company, has released a comprehensive report highlighting the promising future of the biodefense market in the United Kingdom. The report predicts substantial revenue growth and outlines key drivers, challenges, and opportunities shaping the industry.

Access Full Report: https://www.fairfieldmarketresearch.com/report/biodefense-market

The global biodefense market recorded a revenue of US$14.8 billion in 2022, and according to Fairfield Market Research, it is expected to witness impressive growth between 2023 and 2030. The market is projected to achieve a remarkable compound annual growth rate (CAGR) of 6.3% during this period, reaching a valuation of US$24.5 billion by 2030.

The COVID-19 pandemic has brought significant loss of life, economic damage, and global security concerns, reigniting discussions about biodefense. Governments worldwide are expected to expand their budgets for research and development in biodefense treatments, creating substantial revenue generation opportunities. The demand for biodefense products is likely to experience an exponential spike in the next five years, driven by increasing prevalence of infectious diseases and the need to safeguard populations against potential bioterrorist attacks.

The report highlights several key findings. Anthrax remains a leading segment in the biodefense market, with the "others" segment, encompassing viruses such as influenza, cholera, Ebola, and Zika, expected to demonstrate the fastest growth. By end use, the military segment accounts for the largest share in the biodefense industry, while the civil segment shows significant growth potential.

Regionally, North America spearheads the market due to favorable federal funding, while the Asia Pacific region is expected to showcase the fastest growth through 2030. In Europe, top countries have increased their research and development expenditure, contributing to the growth of the biodefense market.

The report also outlines the growth drivers for the biodefense market, including the increasing prevalence of infectious diseases, mounting demand in the wake of potential bioterrorist attacks, growing geo-political conflicts, and technological advances. However, challenges such as market uncertainties, limited profits, and regulatory risks may weaken commercial investments in biodefense products.

Key market players competing in the global biodefense market, as identified in the report, include Emergent BioSolutions, Inc., SIGA Technologies, Inc., Bavarian Nordic A/S, Altimmune, Inc., GSK plc., Sanofi Pasteur, and several others.